Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

CHITOSAN COATED SELENIUM-DONEPEZIL NANOPARTICLES AMELIORATE SCOPOLAMINE-INDUCED MEMORY IMPAIRMENT IN RATS

View through CrossRef
Objective: This study investigated the therapeutic potential of chitosan-coated Selenium-Donepezil Nanoparticles (SeNPs) in a scopolamine-induced rat model of Alzheimer's disease (AD). Methods: Chitosan-coated SeNPs were synthesized and characterized using Field Emission Scanning Electron Microscopy (FE-SEM), Dynamic Light Scattering (DLS), Fourier-Transform Infrared Spectroscopy (FTIR), and Energy-Dispersive X-Ray Spectroscopy (EDAX). The therapeutic potential of SeNPs was evaluated in a scopolamine-induced rat model of AD by assessing spatial memory using the Morris Water Maze (MWM) test and passive avoidance test, as well as measuring oxidative stress markers, including the Ferric-Reducing Ability of Plasma (FRAP) and Malondialdehyde (MDA) levels. Results: The selected formula (F2) of chitosan-coated SeNPs significantly improved spatial memory and reduced oxidative stress markers compared to scopolamine controls, suggesting a synergistic effect. The average size of F2 was approximately 200 nm, with a zeta potential of-20.4 mV. The loading efficiency of donepezil into F2 was 42.3±0.57%. In the MWM test, F2 significantly improved spatial memory and learning compared to the scopolamine group (p<0.01). F2 also ameliorated scopolamine-induced memory deficits in the passive avoidance test (p<0.05). Furthermore, F2 significantly increased FRAP levels and decreased MDA levels in both serum and brain tissue compared to the scopolamine group (p<0.05). Conclusion: The results suggest that chitosan-coated SeNPs may offer a promising therapeutic approach for AD by targeting both oxidative stress and cholinergic dysfunction, warranting further investigation.
Title: CHITOSAN COATED SELENIUM-DONEPEZIL NANOPARTICLES AMELIORATE SCOPOLAMINE-INDUCED MEMORY IMPAIRMENT IN RATS
Description:
Objective: This study investigated the therapeutic potential of chitosan-coated Selenium-Donepezil Nanoparticles (SeNPs) in a scopolamine-induced rat model of Alzheimer's disease (AD).
Methods: Chitosan-coated SeNPs were synthesized and characterized using Field Emission Scanning Electron Microscopy (FE-SEM), Dynamic Light Scattering (DLS), Fourier-Transform Infrared Spectroscopy (FTIR), and Energy-Dispersive X-Ray Spectroscopy (EDAX).
The therapeutic potential of SeNPs was evaluated in a scopolamine-induced rat model of AD by assessing spatial memory using the Morris Water Maze (MWM) test and passive avoidance test, as well as measuring oxidative stress markers, including the Ferric-Reducing Ability of Plasma (FRAP) and Malondialdehyde (MDA) levels.
Results: The selected formula (F2) of chitosan-coated SeNPs significantly improved spatial memory and reduced oxidative stress markers compared to scopolamine controls, suggesting a synergistic effect.
The average size of F2 was approximately 200 nm, with a zeta potential of-20.
4 mV.
The loading efficiency of donepezil into F2 was 42.
3±0.
57%.
In the MWM test, F2 significantly improved spatial memory and learning compared to the scopolamine group (p<0.
01).
F2 also ameliorated scopolamine-induced memory deficits in the passive avoidance test (p<0.
05).
Furthermore, F2 significantly increased FRAP levels and decreased MDA levels in both serum and brain tissue compared to the scopolamine group (p<0.
05).
Conclusion: The results suggest that chitosan-coated SeNPs may offer a promising therapeutic approach for AD by targeting both oxidative stress and cholinergic dysfunction, warranting further investigation.

Related Results

Steady‐State Plasma Concentration of Donepezil Enantiomers and Its Stereoselective Metabolism and Transport In Vitro
Steady‐State Plasma Concentration of Donepezil Enantiomers and Its Stereoselective Metabolism and Transport In Vitro
ABSTRACTThe aim of the present study was to elucidate the differences in the plasma concentration of two enantiomers of donepezil in Chinese patients with Alzheimer's disease (AD) ...
Synthesis and Investigation into Apatite-forming Ability of Hydroxyapatite/Chitosan-based Scaffold
Synthesis and Investigation into Apatite-forming Ability of Hydroxyapatite/Chitosan-based Scaffold
In this study, porous scaffolds were fabricated using inorganic material-hydroxyapatite and chitosan for bone-tissue engineering. The combination of hydroxyapatite and chitosan may...
Evaluation of the neuroprotective effect of donepezil in type 2 diabetic rats
Evaluation of the neuroprotective effect of donepezil in type 2 diabetic rats
AbstractRecent studies raise the possibility that donepezil can delay the progression of Alzheimer’s disease (AD). This research evaluated the efficacy of donepezil in an animal mo...
Aripiprazole ameliorates scopolamine-induced amnesia in mice
Aripiprazole ameliorates scopolamine-induced amnesia in mice
Aripiprazole, a known third generation anti-psychotic drug. The drug has shown to have lesser side effects on extrapyramidal system and enhance memory when compared with the first-...
Donepezil-induced psychosis: a cautionary report of a rare adverse reaction
Donepezil-induced psychosis: a cautionary report of a rare adverse reaction
IntroductionDonepezil is an acetylcholinesterase inhibitor approved by the Food and Drug Administration for the treatment of dementia in Alzheimer’s disease. While it is not curati...
Characterization of chitosan/alginate/lovastatin nanoparticles and investigation of their toxic effects in vitro and in vivo
Characterization of chitosan/alginate/lovastatin nanoparticles and investigation of their toxic effects in vitro and in vivo
AbstractIn this study, chitosan and alginate were selected to prepare alginate/chitosan nanoparticles to load the drug lovastatin by the ionic gelation method. The synthesized nano...
Safety and Tolerability of Donepezil in Mild Cognitive Impairment: Open-Label Extension Study
Safety and Tolerability of Donepezil in Mild Cognitive Impairment: Open-Label Extension Study
Following a 48-week, double-blind, randomized, placebo-controlled trial of donepezil in 821 patients with amnestic mild cognitive impairment (aMCI), safety and tolerability of done...

Back to Top